Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy

Jason M. Jones, Rui Qin, Aditya Bardia, Breanna Linquist, Sherry Wolf, Charles Lawrence Loprinzi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect. Previous studies have primarily focused on prophylactic therapy, but no published reports have evaluated the treatment of breakthrough CINV. Methods: A prospective, pilot study was performed to provide preliminary prospective evidence of the efficacy of individual agents prescribed for the treatment of breakthrough CINV. Enrolled patients were receiving moderately or highly emetogenic chemotherapy and prophylactic treatment of CINV based on antiemetic guidelines. Patients were prescribed an antiemetic for breakthrough CINV at the discretion of their treating oncologist. If patients had breakthrough CINV that required a breakthrough antiemetic medication, they were instructed to complete a questionnaire every 30 minutes for 4 hours after taking the antiemetic. Levels of nausea (0-10), vomiting, and side effects were recorded. Results: Of the 96 patients enrolled, 27 (28%) reported breakthrough nausea and/or vomiting requiring medication and completed the questionniare. Eighty-eight percent (n = 24) reported the use of prochlorperazine; they experienced a 75% median nausea reduction after 4 hours, with minimal side effects. Three patients (12%) reported the use of a 5-hydroxytryptophan (5-HT) receptor antagonist for treatment of breakthrough nausea. These patients reported a median nausea reduction of 75% after 4 hours and no perceived toxicities. Conclusions: Prochlorperazine and 5-HT receptor antagonists appear to be effective breakthrough antiemetic therapies. The described study methodology can be used to conduct randomized clinical trials to find more effective drugs for treating established nausea.

Original languageEnglish (US)
Pages (from-to)810-814
Number of pages5
JournalJournal of Palliative Medicine
Volume14
Issue number7
DOIs
StatePublished - Jul 1 2011

Fingerprint

Antiemetics
Nausea
Vomiting
Drug Therapy
Therapeutics
Prochlorperazine
5-Hydroxytryptophan
Randomized Controlled Trials

ASJC Scopus subject areas

  • Medicine(all)
  • Anesthesiology and Pain Medicine
  • Nursing(all)

Cite this

Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. / Jones, Jason M.; Qin, Rui; Bardia, Aditya; Linquist, Breanna; Wolf, Sherry; Loprinzi, Charles Lawrence.

In: Journal of Palliative Medicine, Vol. 14, No. 7, 01.07.2011, p. 810-814.

Research output: Contribution to journalArticle

Jones, Jason M. ; Qin, Rui ; Bardia, Aditya ; Linquist, Breanna ; Wolf, Sherry ; Loprinzi, Charles Lawrence. / Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. In: Journal of Palliative Medicine. 2011 ; Vol. 14, No. 7. pp. 810-814.
@article{c6c9a38951c04aaab1a931cffa625a2f,
title = "Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy",
abstract = "Background: Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect. Previous studies have primarily focused on prophylactic therapy, but no published reports have evaluated the treatment of breakthrough CINV. Methods: A prospective, pilot study was performed to provide preliminary prospective evidence of the efficacy of individual agents prescribed for the treatment of breakthrough CINV. Enrolled patients were receiving moderately or highly emetogenic chemotherapy and prophylactic treatment of CINV based on antiemetic guidelines. Patients were prescribed an antiemetic for breakthrough CINV at the discretion of their treating oncologist. If patients had breakthrough CINV that required a breakthrough antiemetic medication, they were instructed to complete a questionnaire every 30 minutes for 4 hours after taking the antiemetic. Levels of nausea (0-10), vomiting, and side effects were recorded. Results: Of the 96 patients enrolled, 27 (28{\%}) reported breakthrough nausea and/or vomiting requiring medication and completed the questionniare. Eighty-eight percent (n = 24) reported the use of prochlorperazine; they experienced a 75{\%} median nausea reduction after 4 hours, with minimal side effects. Three patients (12{\%}) reported the use of a 5-hydroxytryptophan (5-HT) receptor antagonist for treatment of breakthrough nausea. These patients reported a median nausea reduction of 75{\%} after 4 hours and no perceived toxicities. Conclusions: Prochlorperazine and 5-HT receptor antagonists appear to be effective breakthrough antiemetic therapies. The described study methodology can be used to conduct randomized clinical trials to find more effective drugs for treating established nausea.",
author = "Jones, {Jason M.} and Rui Qin and Aditya Bardia and Breanna Linquist and Sherry Wolf and Loprinzi, {Charles Lawrence}",
year = "2011",
month = "7",
day = "1",
doi = "10.1089/jpm.2011.0058",
language = "English (US)",
volume = "14",
pages = "810--814",
journal = "Journal of Palliative Medicine",
issn = "1096-6218",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy

AU - Jones, Jason M.

AU - Qin, Rui

AU - Bardia, Aditya

AU - Linquist, Breanna

AU - Wolf, Sherry

AU - Loprinzi, Charles Lawrence

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Background: Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect. Previous studies have primarily focused on prophylactic therapy, but no published reports have evaluated the treatment of breakthrough CINV. Methods: A prospective, pilot study was performed to provide preliminary prospective evidence of the efficacy of individual agents prescribed for the treatment of breakthrough CINV. Enrolled patients were receiving moderately or highly emetogenic chemotherapy and prophylactic treatment of CINV based on antiemetic guidelines. Patients were prescribed an antiemetic for breakthrough CINV at the discretion of their treating oncologist. If patients had breakthrough CINV that required a breakthrough antiemetic medication, they were instructed to complete a questionnaire every 30 minutes for 4 hours after taking the antiemetic. Levels of nausea (0-10), vomiting, and side effects were recorded. Results: Of the 96 patients enrolled, 27 (28%) reported breakthrough nausea and/or vomiting requiring medication and completed the questionniare. Eighty-eight percent (n = 24) reported the use of prochlorperazine; they experienced a 75% median nausea reduction after 4 hours, with minimal side effects. Three patients (12%) reported the use of a 5-hydroxytryptophan (5-HT) receptor antagonist for treatment of breakthrough nausea. These patients reported a median nausea reduction of 75% after 4 hours and no perceived toxicities. Conclusions: Prochlorperazine and 5-HT receptor antagonists appear to be effective breakthrough antiemetic therapies. The described study methodology can be used to conduct randomized clinical trials to find more effective drugs for treating established nausea.

AB - Background: Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect. Previous studies have primarily focused on prophylactic therapy, but no published reports have evaluated the treatment of breakthrough CINV. Methods: A prospective, pilot study was performed to provide preliminary prospective evidence of the efficacy of individual agents prescribed for the treatment of breakthrough CINV. Enrolled patients were receiving moderately or highly emetogenic chemotherapy and prophylactic treatment of CINV based on antiemetic guidelines. Patients were prescribed an antiemetic for breakthrough CINV at the discretion of their treating oncologist. If patients had breakthrough CINV that required a breakthrough antiemetic medication, they were instructed to complete a questionnaire every 30 minutes for 4 hours after taking the antiemetic. Levels of nausea (0-10), vomiting, and side effects were recorded. Results: Of the 96 patients enrolled, 27 (28%) reported breakthrough nausea and/or vomiting requiring medication and completed the questionniare. Eighty-eight percent (n = 24) reported the use of prochlorperazine; they experienced a 75% median nausea reduction after 4 hours, with minimal side effects. Three patients (12%) reported the use of a 5-hydroxytryptophan (5-HT) receptor antagonist for treatment of breakthrough nausea. These patients reported a median nausea reduction of 75% after 4 hours and no perceived toxicities. Conclusions: Prochlorperazine and 5-HT receptor antagonists appear to be effective breakthrough antiemetic therapies. The described study methodology can be used to conduct randomized clinical trials to find more effective drugs for treating established nausea.

UR - http://www.scopus.com/inward/record.url?scp=79959709997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959709997&partnerID=8YFLogxK

U2 - 10.1089/jpm.2011.0058

DO - 10.1089/jpm.2011.0058

M3 - Article

VL - 14

SP - 810

EP - 814

JO - Journal of Palliative Medicine

JF - Journal of Palliative Medicine

SN - 1096-6218

IS - 7

ER -